During intensive and long-lasting treatments, short-term or emergency care, children often undergo minor needle-related ...

Research reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...

TNX-102 SL is a non-opioid, centrally-acting analgesic. Fibromyalgia is a common chronic pain condition that affects mostly women. “Siobhan is an invaluable member of our team and an outstanding ...

H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating ...

It is important to add pain management to leprosy treatment protocols. This can reduce the challenges that patients face. Read on.

The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to ...

Chronic pain is a global health challenge, with current treatment options often limited by side effects, addiction risk, and diminished effectiveness over time. In a new study, Yale researchers ...